Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer

Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer

We investigated the efficacy and safety of concurrent chemoradiotherapy with CDGP/5-FU for 15 head and neck squamous cell carcinomas from July 2004 to March 2008. Seven patients were clinical stage III, six were stage IV A and two were stage IV B. Radiotherapy was 60-66 Gy and two courses of 5-FU 70...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toukeibu Gan 2010/04/25, Vol.36(1), pp.97-100
Hauptverfasser: Abe, Takahisa, Namba, Atsushi, Shirasaki, Takashi, Shinkawa, Hideichi
Format: Artikel
Sprache:jpn
Schlagworte:
CDGP (Nedaplatin)
Concurrent chemoradiotherapy
Head and neck cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 100
container_issue 1
container_start_page 97
container_title Toukeibu Gan
container_volume 36
creator Abe, Takahisa
Namba, Atsushi
Shirasaki, Takashi
Shinkawa, Hideichi
description We investigated the efficacy and safety of concurrent chemoradiotherapy with CDGP/5-FU for 15 head and neck squamous cell carcinomas from July 2004 to March 2008. Seven patients were clinical stage III, six were stage IV A and two were stage IV B. Radiotherapy was 60-66 Gy and two courses of 5-FU 700mg/m2 on days 1-5 and CDGP 70mg/m2 on day five were administered concurrently with radiotherapy. The median follow-up period was 22 months (range 4-41 months). Eleven cases (73.3%) had a complete response to treatment in the primary lesions and three cases (20%) had a partial response. The three-year overall survival rate was 93% and the three-year local control rate was 79%. Grade 3 or greater acute adverse events were leucopenia in 33.3%, thrombocytopenia in 33.3% and pharyngeal mucositis in 26.6%. Concurrent chemoradiotherapy with CDGP/5-FU seemed to be effective for advanced head and neck squamous cell carcinomas.
doi_str_mv 10.5981/jjhnc.36.97
format Article
fullrecord <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5981_jjhnc_36_97</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_jjhnc_36_1_36_1_97_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1307-ad59387253f47755d1024020bb89f44d035460f8bc199582540c466093809b4f3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EElXpih_wHqUdv2J7B0ppQaoEC7q2HMcmCa1TOUGof0-gqGzmjnTPzOIgdEtgLrQii7ato5uzfK7lBZoQpUimmKKX4864zoTk8hrN-r4pAQhRlHA6Qcuii-4zJR8H7Gq_75Ktmm6ofbKHI_5qhhoXy_XrQmSrLQ5dwrW3FbaxwtG7D-xsdD7doKtgd72f_eUUbVePb8VTtnlZPxcPm8wRBjKzldBMSSpY4FIKURGgHCiUpdKB8wqY4DkEVTqitVBUcHA8z2E8Al3ywKbo7vTXpa7vkw_mkJq9TUdDwPw4ML8ODMuNliN9f6LbfrDv_szaNDRu5_9ZchpanitX22R8ZN9lg2TM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer</title><source>J-STAGE Free</source><creator>Abe, Takahisa ; Namba, Atsushi ; Shirasaki, Takashi ; Shinkawa, Hideichi</creator><creatorcontrib>Abe, Takahisa ; Namba, Atsushi ; Shirasaki, Takashi ; Shinkawa, Hideichi</creatorcontrib><description>We investigated the efficacy and safety of concurrent chemoradiotherapy with CDGP/5-FU for 15 head and neck squamous cell carcinomas from July 2004 to March 2008. Seven patients were clinical stage III, six were stage IV A and two were stage IV B. Radiotherapy was 60-66 Gy and two courses of 5-FU 700mg/m2 on days 1-5 and CDGP 70mg/m2 on day five were administered concurrently with radiotherapy. The median follow-up period was 22 months (range 4-41 months). Eleven cases (73.3%) had a complete response to treatment in the primary lesions and three cases (20%) had a partial response. The three-year overall survival rate was 93% and the three-year local control rate was 79%. Grade 3 or greater acute adverse events were leucopenia in 33.3%, thrombocytopenia in 33.3% and pharyngeal mucositis in 26.6%. Concurrent chemoradiotherapy with CDGP/5-FU seemed to be effective for advanced head and neck squamous cell carcinomas.</description><identifier>ISSN: 1349-5747</identifier><identifier>EISSN: 1881-8382</identifier><identifier>DOI: 10.5981/jjhnc.36.97</identifier><language>jpn</language><publisher>Japan Society for Head and Neck Cancer</publisher><subject>CDGP (Nedaplatin) ; Concurrent chemoradiotherapy ; Head and neck cancer</subject><ispartof>Toukeibu Gan, 2010/04/25, Vol.36(1), pp.97-100</ispartof><rights>2010 Japan Society for Head and Neck Cancer</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1307-ad59387253f47755d1024020bb89f44d035460f8bc199582540c466093809b4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids></links><search><creatorcontrib>Abe, Takahisa</creatorcontrib><creatorcontrib>Namba, Atsushi</creatorcontrib><creatorcontrib>Shirasaki, Takashi</creatorcontrib><creatorcontrib>Shinkawa, Hideichi</creatorcontrib><title>Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer</title><title>Toukeibu Gan</title><addtitle>Toukeibu Gan</addtitle><description>We investigated the efficacy and safety of concurrent chemoradiotherapy with CDGP/5-FU for 15 head and neck squamous cell carcinomas from July 2004 to March 2008. Seven patients were clinical stage III, six were stage IV A and two were stage IV B. Radiotherapy was 60-66 Gy and two courses of 5-FU 700mg/m2 on days 1-5 and CDGP 70mg/m2 on day five were administered concurrently with radiotherapy. The median follow-up period was 22 months (range 4-41 months). Eleven cases (73.3%) had a complete response to treatment in the primary lesions and three cases (20%) had a partial response. The three-year overall survival rate was 93% and the three-year local control rate was 79%. Grade 3 or greater acute adverse events were leucopenia in 33.3%, thrombocytopenia in 33.3% and pharyngeal mucositis in 26.6%. Concurrent chemoradiotherapy with CDGP/5-FU seemed to be effective for advanced head and neck squamous cell carcinomas.</description><subject>CDGP (Nedaplatin)</subject><subject>Concurrent chemoradiotherapy</subject><subject>Head and neck cancer</subject><issn>1349-5747</issn><issn>1881-8382</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpFkMtOwzAQRS0EElXpih_wHqUdv2J7B0ppQaoEC7q2HMcmCa1TOUGof0-gqGzmjnTPzOIgdEtgLrQii7ato5uzfK7lBZoQpUimmKKX4864zoTk8hrN-r4pAQhRlHA6Qcuii-4zJR8H7Gq_75Ktmm6ofbKHI_5qhhoXy_XrQmSrLQ5dwrW3FbaxwtG7D-xsdD7doKtgd72f_eUUbVePb8VTtnlZPxcPm8wRBjKzldBMSSpY4FIKURGgHCiUpdKB8wqY4DkEVTqitVBUcHA8z2E8Al3ywKbo7vTXpa7vkw_mkJq9TUdDwPw4ML8ODMuNliN9f6LbfrDv_szaNDRu5_9ZchpanitX22R8ZN9lg2TM</recordid><startdate>20100425</startdate><enddate>20100425</enddate><creator>Abe, Takahisa</creator><creator>Namba, Atsushi</creator><creator>Shirasaki, Takashi</creator><creator>Shinkawa, Hideichi</creator><general>Japan Society for Head and Neck Cancer</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20100425</creationdate><title>Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer</title><author>Abe, Takahisa ; Namba, Atsushi ; Shirasaki, Takashi ; Shinkawa, Hideichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1307-ad59387253f47755d1024020bb89f44d035460f8bc199582540c466093809b4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2010</creationdate><topic>CDGP (Nedaplatin)</topic><topic>Concurrent chemoradiotherapy</topic><topic>Head and neck cancer</topic><toplevel>online_resources</toplevel><creatorcontrib>Abe, Takahisa</creatorcontrib><creatorcontrib>Namba, Atsushi</creatorcontrib><creatorcontrib>Shirasaki, Takashi</creatorcontrib><creatorcontrib>Shinkawa, Hideichi</creatorcontrib><collection>CrossRef</collection><jtitle>Toukeibu Gan</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abe, Takahisa</au><au>Namba, Atsushi</au><au>Shirasaki, Takashi</au><au>Shinkawa, Hideichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer</atitle><jtitle>Toukeibu Gan</jtitle><addtitle>Toukeibu Gan</addtitle><date>2010-04-25</date><risdate>2010</risdate><volume>36</volume><issue>1</issue><spage>97</spage><epage>100</epage><pages>97-100</pages><issn>1349-5747</issn><eissn>1881-8382</eissn><abstract>We investigated the efficacy and safety of concurrent chemoradiotherapy with CDGP/5-FU for 15 head and neck squamous cell carcinomas from July 2004 to March 2008. Seven patients were clinical stage III, six were stage IV A and two were stage IV B. Radiotherapy was 60-66 Gy and two courses of 5-FU 700mg/m2 on days 1-5 and CDGP 70mg/m2 on day five were administered concurrently with radiotherapy. The median follow-up period was 22 months (range 4-41 months). Eleven cases (73.3%) had a complete response to treatment in the primary lesions and three cases (20%) had a partial response. The three-year overall survival rate was 93% and the three-year local control rate was 79%. Grade 3 or greater acute adverse events were leucopenia in 33.3%, thrombocytopenia in 33.3% and pharyngeal mucositis in 26.6%. Concurrent chemoradiotherapy with CDGP/5-FU seemed to be effective for advanced head and neck squamous cell carcinomas.</abstract><pub>Japan Society for Head and Neck Cancer</pub><doi>10.5981/jjhnc.36.97</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1349-5747
ispartof Toukeibu Gan, 2010/04/25, Vol.36(1), pp.97-100
issn 1349-5747
1881-8382
language jpn
recordid cdi_crossref_primary_10_5981_jjhnc_36_97
source J-STAGE Free
subjects CDGP (Nedaplatin)
Concurrent chemoradiotherapy
Head and neck cancer
title Concurrent chemoradiotherapy with CDGP/5-FU for head and neck cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T09%3A57%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concurrent%20chemoradiotherapy%20with%20CDGP/5-FU%20for%20head%20and%20neck%20cancer&rft.jtitle=Toukeibu%20Gan&rft.au=Abe,%20Takahisa&rft.date=2010-04-25&rft.volume=36&rft.issue=1&rft.spage=97&rft.epage=100&rft.pages=97-100&rft.issn=1349-5747&rft.eissn=1881-8382&rft_id=info:doi/10.5981/jjhnc.36.97&rft_dat=%3Cjstage_cross%3Earticle_jjhnc_36_1_36_1_97_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true